[en] This International Myeloma Working Group consensus updates the disease defi nition of multiple myeloma to include validated biomarkers in addition to existing requirements of attributable CRAB features (hypercalcaemia, renal failure, anaemia, and bone lesions). These changes are based on the identifi cation of biomarkers associated with near inevitable development of CRAB features in patients who would otherwise be regarded as having smouldering multiple myeloma. A delay in application of the label of multiple myeloma and postponement of therapy could be detrimental to these patients. In addition to this change, we clarify and update the underlying laboratory and
radiographic variables that fulfi l the criteria for the presence of myeloma-defi ning CRAB features, and the histological and monoclonal protein requirements for the disease diagnosis. Finally, we provide specifi c metrics that new biomarkers should meet for inclusion in the disease defi nition. The International Myeloma Working Group recommends the implementation of these criteria in routine practice and in future clinical trials, and recommends that future studies analyse any diff erences in outcome that might occur as a result of the new disease defi nition.
Disciplines :
Hématologie
Auteur, co-auteur :
Rajkumar, Vincent
Dimopoulos, Meletios
Palumbo, Antonio
Blade, Joan
Merlini, Giampaolo
Mateos, Maria-Victoria
Kumar, Shaji
Hillengass, Jens
Kastritis, Efstathios
Richardson, Paul
Landgren, Ola
Paiva, Bruno
Dispenzieri, Angela
Weiss, Brendan
Leleu, Xavier
Zweegman, Sonja
Lonial, Sagar
Rosinol, Laura
Zamagni, Elena
Jagannath, Sundar
Sezer, Orhan
Kristinsson, Sigurdur
CAERS, Jo ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique
Landgren O, Kyle RA, Pfeiffer RM, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 2009, 113:5412-5417.
Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 2009, 113:5418-5422.
Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006, 354:1362-1369.
Landgren O, Graubard BI, Katzmann JA, et al. Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and Nutritional Examination Survey. Leukemia 2014, 28:1537-1542.
Bladé J Monoclonal gammopathy of undetermined significance. N Engl J Med 2006, 355:2765-2770.
Dispenzieri A, Katzmann JA, Kyle RA, et al. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet 2010, 375:1721-1728.
Merlini G, Palladini G Differential diagnosis of monoclonal gammopathy of undetermined significance. Hematology (Am Soc Hematol Educ Program) 2012, 2012:595-603.
Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003, 121:749-757. International Myeloma Working Group.
Kyle RA, Rajkumar SV Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009, 23:3-9.
Kyle RA, Larson DR, Therneau TM, et al. Clinical course of light-chain smouldering multiple myeloma (idiopathic Bence Jones proteinuria): a retrospective study. Lancet Haematol 2014, 1:e28-e36.
Dimopoulos MA, Kiamouris C, Moulopoulos LA Solitary plasmacytoma of bone and extramedullary plasmacytoma. Hematol Oncol Clin North Am 1999, 13:1249-1257.
Hill QA, Rawstron AC, de Tute RM, Owen RG Outcome prediction in solitary plasmacytoma of bone: a risk stratification model utilizing bone marrow flow cytometry and light-chain analysis. Blood 2014, 124:1296-1299.
Paiva B, Chandia M, Vidriales MB, et al. Multiparameter flow cytometry for staging of solitary bone plasmacytoma: new criteria for risk of progression to myeloma. Blood 2014, 124:1300-1303.
Warsame R, Gertz MA, Lacy MQ, et al. Trends and outcomes of modern staging of solitary plasmacytoma of bone. Am J Hematol 2012, 87:647-651.
Dispenzieri A, Kyle RA, Lacy MQ, et al. POEMS syndrome: definitions and long-term outcome. Blood 2003, 101:2496-2506.
Rajkumar SV, Dispenzieri A, Kyle RA Monoclonal gammopathy of undetermined significance, Waldenström macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment. Mayo Clin Proc 2006, 81:693-703.
Dispenzieri A POEMS syndrome. Blood Rev 2007, 21:285-299.
Kyle RA, Therneau TM, Rajkumar SV, et al. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood 2003, 102:3759-3764.
Kyle RA, Durie BGM, Rajkumar SV, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 2010, 24:1121-1127. the International Myeloma Working Group.
Landgren O Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: biological insights and early treatment strategies. Hematology (Am Soc Hematol Educ Program) 2013, 2013:478-487.
Schuster SR, Rajkumar SV, Dispenzieri A, et al. IgM multiple myeloma: disease definition, prognosis, and differentiation from Waldenstrom's macroglobulinemia. Am J Hematol 2010, 85:853-855.
Turesson I, Kovalchik SA, Pfeiffer RM, et al. Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden. Blood 2014, 123:338-345.
Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002, 346:564-569.
Cesana C, Klersy C, Barbarano L, et al. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. J Clin Oncol 2002, 20:1625-1634.
Rajkumar SV, Kyle RA, Therneau TM, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 2005, 106:812-817.
Pérez-Persona E, Vidriales MB, Mateo G, et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood 2007, 110:2586-2592.
Katzmann JA, Clark R, Kyle RA, et al. Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS. Leukemia 2013, 27:208-212.
Kyle RA, Remstein ED, Therneau TM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med 2007, 356:2582-2590.
Cherry BM, Korde N, Kwok M, et al. Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study. Leuk Lymphoma 2013, 54:2215-2218.
Kristinsson SY, Holmberg E, Blimark C Treatment for high-risk smoldering myeloma. N Engl J Med 2013, 369:1762-1763.
Rajkumar SV Preventive strategies in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Am J Hematol 2012, 87:453-454.
Rajkumar SV, Merlini G, San Miguel JF Haematological cancer: Redefining myeloma. Nat Rev Clin Oncol 2012, 9:494-496.
Landgren O, Waxman AJ Multiple myeloma precursor disease. JAMA 2010, 304:2397-2404.
Dimopoulos M, Kyle R, Fermand JP, et al. Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood 2011, 117:4701-4705. the International Myeloma Workshop Consensus Panel 3.
Rajkumar SV, Harousseau JL, Durie B, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 2011, 117:4691-4695. the International Myeloma Workshop Consensus Panel 1.
Mateos M-V, Hernández M-T, Giraldo P, et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med 2013, 369:438-447.
Dispenzieri A, Stewart AK, Chanan-Khan A, et al. Smoldering multiple myeloma requiring treatment: time for a new definition?. Blood 2013, 122:4172-4181.
Mailankody S, Mena E, Yuan CM, Balakumaran A, Kuehl WM, Landgren O Molecular and biologic markers of progression in monoclonal gammopathy of undetermined significance to multiple myeloma. Leuk Lymphoma 2010, 51:2159-2170.
Landgren O, Rajkumar SV Development of early treatment strategies for high-risk myeloma precursor disease in the future. Semin Hematol 2011, 48:66-72.
Landgren O Multiple myeloma precursor disease: current clinical dilemma and future opportunities. Semin Hematol 2011, 48:1-3.
Rajkumar SV Prevention of progression in monoclonal gammopathy of undetermined significance. Clin Cancer Res 2009, 15:5606-5608.
Dispenzieri A, Kyle RA, Katzmann JA, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood 2008, 111:785-789.
Rajkumar SV, Larson D, Kyle RA Diagnosis of smoldering multiple myeloma. N Engl J Med 2011, 365:474-475.
Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005, 352:2487-2498. the Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators.
Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007, 357:2123-2132. the Multiple Myeloma (010) Study Investigators.
Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010, 11:29-37. the Eastern Cooperative Oncology Group.
Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010, 116:679-686.
Jakubowiak AJ, Dytfeld D, Griffith KA, et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood 2012, 120:1801-1809.
Lacy MQ, Hayman SR, Gertz MA, et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol 2009, 27:5008-5014.
Hjorth M, Hellquist L, Holmberg E, Magnusson B, Rödjer S, Westin J Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I-a randomized study. Eur J Haematol 1993, 50:95-102. the Myeloma Group of Western Sweden.
Riccardi A, Mora O, Tinelli C, et al. Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. Br J Cancer 2000, 82:1254-1260. the Cooperative Group of Study and Treatment of Multiple Myeloma.
Dimopoulos M, Terpos E, Comenzo RL, et al. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma. Leukemia 2009, 23:1545-1556. the IMWG.
Hillengass J, Landgren O Challenges and opportunities of novel imaging techniques in monoclonal plasma cell disorders: imaging "early myeloma". Leuk Lymphoma 2013, 54:1355-1363.
Regelink JC, Minnema MC, Terpos E, et al. Comparison of modern and conventional imaging techniques in establishing multiple myeloma-related bone disease: a systematic review. Br J Haematol 2013, 162:50-61.
Kastritis E, Terpos E, Moulopoulos L, et al. Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease. Leukemia 2013, 27:947-953.
Waxman AJ, Mick R, Garfall AL, et al. Modeling the risk of progression in smoldering multiple myeloma. Proc Am Soc Clin Oncol 2014, 32:A8607. (abstr).
Johnsen HE, Bøgsted M, Klausen TW, et al. Multiparametric flow cytometry profiling of neoplastic plasma cells in multiple myeloma. Cytometry B Clin Cytom 2010, 78:338-347. the Nordic Myeloma Study (NMSG), the Myeloma Stem Cell Network (MSCNET)the Myeloma Stem Cell Network (MSCNET).
Rajkumar SV, Fonseca R, Dispenzieri A, et al. Methods for estimation of bone marrow plasma cell involvement in myeloma: predictive value for response and survival in patients undergoing autologous stem cell transplantation. Am J Hematol 2001, 68:269-275.
Bradwell AR, Carr-Smith HD, Mead GP, et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 2001, 47:673-680.
Katzmann JA, Clark RJ, Abraham RS, et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 2002, 48:1437-1444.
Bradwell AR, Carr-Smith HD, Mead GP, Harvey TC, Drayson MT Serum test for assessment of patients with Bence Jones myeloma. Lancet 2003, 361:489-491.
Dispenzieri A, Kyle R, Merlini G, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009, 23:215-224. the International Myeloma Working Group.
Kyrtsonis MC, Vassilakopoulos TP, Kafasi N, et al. Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma. Br J Haematol 2007, 137:240-243.
Snozek CLH, Katzmann JA, Kyle RA, et al. Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system. Leukemia 2008, 22:1933-1937.
Dingli D, Kyle RA, Rajkumar SV, et al. Immunoglobulin free light chains and solitary plasmacytoma of bone. Blood 2006, 108:1979-1983.
Larsen JT, Kumar SK, Dispenzieri A, Kyle RA, Katzmann JA, Rajkumar SV Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. Leukemia 2013, 27:941-946.
Moulopoulos LA, Dimopoulos MA, Smith TL, et al. Prognostic significance of magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol 1995, 13:251-256.
Mariette X, Zagdanski AM, Guermazi A, et al. Prognostic value of vertebral lesions detected by magnetic resonance imaging in patients with stage I multiple myeloma. Br J Haematol 1999, 104:723-729.
Wang M, Alexanian R, Delasalle K, Weber D Abnormal MRI of spine is the dominant risk factor for early progression of asymptomatic multiple myeloma. Blood 2003, 102:687a.
Hillengass J, Fechtner K, Weber MA, et al. Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol 2010, 28:1606-1610.
Kastritis E, Moulopoulos LA, Terpos E, Koutoulidis V, Dimopoulos MA The prognostic importance of the presence of more than one focal lesion in spine MRI of patients with asymptomatic (smoldering) multiple myeloma. Leukemia 2014, published online July 31. 10.1038/leu.2014.230.
Dimopoulos MA, Moulopoulos A, Smith T, Delasalle KB, Alexanian R Risk of disease progression in asymptomatic multiple myeloma. Am J Med 1993, 94:57-61.
Weber DM, Dimopoulos MA, Moulopoulos LA, Delasalle KB, Smith T, Alexanian R Prognostic features of asymptomatic multiple myeloma. Br J Haematol 1997, 97:810-814.
Merz M, Hielscher T, Wagner B, et al. Predictive value of longitudinal whole-body magnetic resonance imaging in patients with smoldering multiple myeloma. Leukemia 2014, 28:1902-1908.
Zamagni E, Cavo M The role of imaging techniques in the management of multiple myeloma. Br J Haematol 2012, 159:499-513.
Zamagni E, Nanni C, Patriarca F, et al. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica 2007, 92:50-55.
Walker R, Barlogie B, Haessler J, et al. Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol 2007, 25:1121-1128.
Bartel TB, Haessler J, Brown TL, et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood 2009, 114:2068-2076.
Waheed S, Mitchell A, Usmani S, et al. Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data. Haematologica 2013, 98:71-78.
Leung N, Bridoux F, Hutchison CA, et al. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood 2012, 120:4292-4295. the International Kidney and Monoclonal Gammopathy Research Group.
Hutchison CA, Batuman V, Behrens J, et al. The pathogenesis and diagnosis of acute kidney injury in multiple myeloma. Nat Rev Nephrol 2012, 8:43-51. the International Kidney and Monoclonal Gammopathy Research Group.
Katzmann JA, Abraham RS, Dispenzieri A, Lust JA, Kyle RA Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice. Clin Chem 2005, 51:878-881.
Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003, 78:21-33.
Dimopoulos MA, Pouli A, Anagnostopoulos A, et al. Macrofocal multiple myeloma in young patients: a distinct entity with favorable prognosis. Leuk Lymphoma 2006, 47:1553-1556.
Dispenzieri A How I treat POEMS syndrome. Blood 2012, 119:5650-5658.
Kourelis TV, Kumar SK, Gertz MA, et al. Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. J Clin Oncol 2013, 31:4319-4324.
Nobile-Orazio E Neuropathy and monoclonal gammopathy. Handb Clin Neurol 2013, 115:443-459.
Dispenzieri A POEMS syndrome: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol 2014, 89:214-223.
Lacy MQ, Gertz MA, Hanson CA, Inwards DJ, Kyle RA Multiple myeloma associated with diffuse osteosclerotic bone lesions: a clinical entity distinct from osteosclerotic myeloma (POEMS syndrome). Am J Hematol 1997, 56:288-293.
Bianchi G, Kyle RA, Larson DR, et al. High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma. Leukemia 2013, 27:680-685.
Pérez-Persona E, Mateo G, García-Sanz R, et al. Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells. Br J Haematol 2010, 148:110-114.
Rawstron AC, Orfao A, Beksac M, et al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica 2008, 93:431-438. the European Myeloma Network.
Rosiñol L, Bladé J, Esteve J, et al. Smoldering multiple myeloma: natural history and recognition of an evolving type. Br J Haematol 2003, 123:631-636.
Rajkumar SV, Gupta V, Fonseca R, et al. Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. Leukemia 2013, 27:1738-1744.
Neben K, Jauch A, Hielscher T, et al. Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load. J Clin Oncol 2013, 31:4325-4332.
Madan S, Kyle RA, Greipp PR Plasma cell labeling index in the evaluation of smoldering (asymptomatic) multiple myeloma. Mayo Clin Proc 2010, 85:300.
Dhodapkar MV, Sexton R, Waheed S, et al. Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). Blood 2014, 123:78-85.
